Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -53.81% is 149% below its 4-year average of -21.62%, near the low end of its 4-year range (-53.81%–-10.52%).
68.71% below its 12-month average of -31.90%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -15.82%.
RETURN ON ASSETS (ROA)
-53.81%
RETURN ON ASSETS (ROA) AVG TTM
-31.90%
RETURN ON ASSETS (ROA) AVG 3Y
-23.26%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-68.71%
CURRENT VS 3Y AVG
-131.39%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.48%
median of 782 covered companies
CURRENT VS SECTOR MEDIAN
-70.96%
vs the sector median at left
Metagenomi, Inc. Common Stock
Market Cap
$40.09M
Return on Assets (ROA)
-53.81%
TTM Avg
-31.90%
3Y Avg
-23.26%
5Y Avg
N/A
Market Cap
$40.22M
Return on Assets (ROA)
-40.69%
TTM Avg
-38.43%
3Y Avg
-19.21%
5Y Avg
-15.37%
Market Cap
$39.84M
Return on Assets (ROA)
11.01%
TTM Avg
4.71%
3Y Avg
-17.75%
5Y Avg
-20.00%
Market Cap
$38.61M
Return on Assets (ROA)
-13.65%
TTM Avg
-40.30%
3Y Avg
-22.41%
5Y Avg
-15.81%
Market Cap
$41.92M
Return on Assets (ROA)
-5.70%
TTM Avg
-13.47%
3Y Avg
-29.01%
5Y Avg
-32.57%
Market Cap
$37.93M
Return on Assets (ROA)
-26.45%
TTM Avg
-127.88%
3Y Avg
-142.31%
5Y Avg
-121.77%
Market Cap
$37.60M
Return on Assets (ROA)
-110.85%
TTM Avg
-107.44%
3Y Avg
-115.17%
5Y Avg
-101.88%
Market Cap
$37.18M
Return on Assets (ROA)
-120.78%
TTM Avg
-168.59%
3Y Avg
-147.82%
5Y Avg
-131.31%
Market Cap
$43.51M
Return on Assets (ROA)
39.10%
TTM Avg
-36.27%
3Y Avg
-59.86%
5Y Avg
-86.70%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Metagenomi, Inc. Common Stock (MGX) | $40.09M | -53.81% | -31.90% | -23.26% | N/A |
| Filana Therapeutics, Inc. (FLNA)vs › | $40.22M | -40.69% | -38.43% | -19.21% | -15.37% |
| Nephros, Inc. (NEPH)vs › | $39.84M | 11.01% | 4.71% | -17.75% | -20.00% |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.61M | -13.65% | -40.30% | -22.41% | -15.81% |
| Precipio, Inc. (PRPO)vs › | $41.92M | -5.70% | -13.47% | -29.01% | -32.57% |
| Incannex Healthcare Limited (IXHL)vs › | $37.93M | -26.45% | -127.88% | -142.31% | -121.77% |
| Edesa Biotech, Inc. (EDSA)vs › | $37.60M | -110.85% | -107.44% | -115.17% | -101.88% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $37.18M | -120.78% | -168.59% | -147.82% | -131.31% |
| SANUWAVE Health Inc. (SNWV)vs › | $43.51M | 39.10% | -36.27% | -59.86% | -86.70% |
| BioStem Technologies, Inc. (BSEM)vs › | $43.65M | -57.95% | 4.78% | -64.05% | -66.64% |
ROA
-53.8%
ROE
-83.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -39.74% |
| 2024-12-31 | -24.05% |
| 2023-12-31 | -18.71% |
| 2022-12-31 | -10.52% |
| 2021-12-31 | -15.10% |
